|Dotinurad is a potent selective urate reabsorption inhibitor. Dotinurad inhibits Urate Transporter 1 (URAT1), IC50 value is 37.2 nM. Dotinurad is used as a uric acid-enhancing excretor.
|Verinurad, also known as RDEA3170, is an organic anion transporter URAT1 inhibitor with an IC50 of 25 nM.
|Lesinurad is a URAT1 and OAT inhibitor, is determined to be a substrate for the kidney transporters OAT1 and OAT3 with Km values of 0.85 and 2 µM, respectively.
|KPH2f is an orally potent dual URAT1/GLUT9 inhibitor, with IC50s of 0.24 μM and 9.37 μM for URAT1 and GLUT9, respectively.KPH2f had little effect on OAT1 and ABCG2 (IC50s of 32.14 and 26.74 μM, respectively).
|URAT1 inhibitor 8
|URAT1 inhibitor 8 is a potent URAT1 inhibitor with an IC50 of 0.001 μM.URAT1 inhibitor 8 can be used in gout related studies.
|URAT1 inhibitor 1
|URAT1 inhibitor 1 is a uric acid transporter 1 (URAT1) inhibitor with an IC50 value of 32 nM for inhibition of uric acid transporter 1 (URAT1).It can be used in studies related to hyperuricemia and gout.
|URAT1 inhibitor 3
|URAT1 inhibitor 3 is an orally potent and selective URAT1 inhibitor with an IC50 value of 0.8 nM.URAT1 inhibitor 3 has a uric acid lowering effect and can be used in studies related to gout and hyperuricemia.
|AR882 is a potential best-in-class (BIC), selective inhibitor of uric acid transporter protein 1 (URAT1) for studies related to hyperuricemia and gout.
|Ruzinurad is a highly selective URATl inhibitor for hyperuricemia.
|AR-882 is a URAT1 inhibitor that can be used in studies related to gout and hyperuricemia.
|RLBN-1127 is an inhibitor of URAT1 and xanthine oxidase (XO) and can be used in studies related to non-alcoholic fatty liver disease (NAFLD) and gout.
|URAT1 inhibitor 7
|URAT1 inhibitor 7 is a potent URAT1 inhibitor, with an IC50 of 12 nM.
|URAT1 inhibitor 6
|URAT1 inhibitor 6 is a potent URAT1 inhibitor (IC50: 35 nM for hURAT1).
|Lingdolinurad is urate transporter inhibitor, targeting to hURAT1.Lingdolinurad can be used for research in hyperuricemia in vitro and in vivo.
|Puliginurad (YL-90148) is a potent, selective inhibitor of urate transporter protein (URAT) that can be used in studies related to hyperuricemia and gout by inhibiting the reabsorption of uric acid at the renal proximal tubule, thereby excreting more uric acid through the urine.
|Epaminurad (UR-1102) is an orally active, potent and selective URAT1 (urate transporter 1) inhibitor, with a Ki of 0.057 μM. Epaminurad quite modestly inhibits OAT1 and OAT3 (organic anion transporter). Epaminurad is a uricosuric agent. Epaminurad can be used for gout and hyperuricemia research.
|Xininurad (XNW3009) is a urate transporter (URAT) inhibitor.
|HR011303 is a novel and highly selective urate transporter 1 (URAT1) inhibitor.
|Lesinurad sodium is a URAT1 and OAT inhibitor, is determined to be a substrate for the kidney transporters OAT1 and OAT3 with Km values of 0.85 and 2 µM, respectively.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.